These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36649820)

  • 1. The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain.
    Prior H; Andrews L; Cauvin A; Chien H; Clarke DO; Datta K; Dempster M; Dybdal N; Freebern W; de Haan L; Herzyk D; Hey A; Kissner T; Kronenberg S; Leach MW; Lee D; Reid K; Schutte K; Sewell F; Trouba K; Ulrich P; van Aerts L; van Meer P; Weir L
    Regul Toxicol Pharmacol; 2023 Feb; 138():105339. PubMed ID: 36649820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach.
    Chien HT; Prior H; Andrews L; van Aerts L; Cauvin A; Clarke DO; Datta K; Dempster M; Dybdal N; Freebern W; de Haan L; Herzyk D; Hey A; Kissner T; Kronenberg S; Leach MW; Lee D; Schutte K; Sewell F; Trouba K; Ulrich P; Weir L; van Meer P
    Regul Toxicol Pharmacol; 2023 Feb; 138():105329. PubMed ID: 36592682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.
    Sewell F; Chapman K; Baldrick P; Brewster D; Broadmeadow A; Brown P; Burns-Naas LA; Clarke J; Constan A; Couch J; Czupalla O; Danks A; DeGeorge J; de Haan L; Hettinger K; Hill M; Festag M; Jacobs A; Jacobson-Kram D; Kopytek S; Lorenz H; Moesgaard SG; Moore E; Pasanen M; Perry R; Ragan I; Robinson S; Schmitt PM; Short B; Lima BS; Smith D; Sparrow S; van Bekkum Y; Jones D
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):413-29. PubMed ID: 25078890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.
    Sewell F; Chapman K; Couch J; Dempster M; Heidel S; Loberg L; Maier C; Maclachlan TK; Todd M; van der Laan JW
    MAbs; 2017 Jul; 9(5):742-755. PubMed ID: 28475417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.
    Prior H; Baldrick P; Beken S; Booler H; Bower N; Brooker P; Brown P; Burlinson B; Burns-Naas LA; Casey W; Chapman M; Clarke D; de Haan L; Doehr O; Downes N; Flaherty M; Gellatly N; Moesgaard SG; Harris J; Holbrook M; Hui J; Jones D; Jones K; Kedar H; Mahl A; Manninen A; McGuire A; Mortimer-Cassen E; Peraza M; Pugsley MK; Richard J; Roberts R; Roosen W; Rothfuss A; Schoenmakers A; Sewell F; Weaver R; Weir L; Wolfreys A; Kimber I
    Regul Toxicol Pharmacol; 2020 Jun; 113():104624. PubMed ID: 32126256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Definition of "Similar Toxicities": Case Studies Illustrating Industry and Regulatory Interpretation of ICH S6(R1) for Long-Term Toxicity Studies in One or Two Species.
    Prior H; Clarke DO; Jones D; Salicru E; Schutten MM; Sewell F
    Int J Toxicol; 2022; 41(3):171-181. PubMed ID: 35435047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
    Lynch CM; Hart BW; Grewal IS
    MAbs; 2009; 1(1):2-11. PubMed ID: 20046568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.
    Perry R; Farris G; Bienvenu JG; Dean C; Foley G; Mahrt C; Short B;
    Toxicol Pathol; 2013; 41(8):1159-69. PubMed ID: 23531793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.
    Chapman KL; Andrews L; Bajramovic JJ; Baldrick P; Black LE; Bowman CJ; Buckley LA; Coney LA; Couch J; Maggie Dempster A; de Haan L; Jones K; Pullen N; de Boer AS; Sims J; Ian Ragan C
    Regul Toxicol Pharmacol; 2012 Mar; 62(2):347-54. PubMed ID: 22100994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicologic Pathology Forum: Opinion on Not Euthanizing Control Animals in the Recovery Phase of Non-Rodent Toxicology Studies.
    Janardhan KS; Sura R; Salian-Mehta S; Flandre T; Palazzi X; Zane D; Singh B; Jacob B; Hukkanen RR; Al-Haddawi M; Bennet B; Laast V; Lee D; Peterson R; Romeike A; Schorsch F; Guffroy M
    Toxicol Pathol; 2022 Dec; 50(8):950-956. PubMed ID: 36226581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.
    Chapman K; Pullen N; Coney L; Dempster M; Andrews L; Bajramovic J; Baldrick P; Buckley L; Jacobs A; Hale G; Green C; Ragan I; Robinson V
    MAbs; 2009; 1(5):505-16. PubMed ID: 20065651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New challenges and opportunities in nonclinical safety testing of biologics.
    Baumann A; Flagella K; Forster R; de Haan L; Kronenberg S; Locher M; Richter WF; Theil FP; Todd M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):226-33. PubMed ID: 24755365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
    Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
    MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment.
    Brennan FR; Cavagnaro J; McKeever K; Ryan PC; Schutten MM; Vahle J; Weinbauer GF; Marrer-Berger E; Black LE
    MAbs; 2018 Jan; 10(1):1-17. PubMed ID: 28991509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
    Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
    Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
    de Zafra CLZ; Sasseville VG; Matsumoto S; Freichel C; Milton M; MacLachlan TK; Farman C; Raymond I; Gupta S; Newton R; Atzpodien EA; Thackaberry EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():221-230. PubMed ID: 28322894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.